Comparison of the safety and effectiveness of drug-coated balloons and drug-eluting stents for coronary heart disease in situ macrovascular disease: a real-world study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046942

Enrollment

Unknown

Registered

2021-05-31

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

drug-coated balloons vs. drug-eluting stents :No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. There are indications for PCI (for example, acute coronary syndrome, stable angina), and the diameter of the blood vessel is >3.0mm; 2. Successfully pre-dilate the lesion before surgery without high-grade dissection (type C to F), reduced blood flow (myocardial infarction thrombus score = 30%; 3. Agree to receive DCB or DES treatment.

Exclusion criteria

Exclusion criteria: 1. Restenosis in the stent; 2. Subjects whose life expectancy is less than 12 months, pregnant, and other clinical studies; 3. Those who refuse to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
minimum lumen diameter; percent diameter stenosis;late lumen acquirement;late lumen loses;target lesion revascularization;re-stenosis in stent;major adverse cardiovascular events;	—

Countries

China

Contacts

Public ContactChu Yingjie

Henan Provincial People's Hospital

hnqbdsl@126.com+86 13937199780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026